OREANDA-NEWS. JSC "Grindeks" informs that the Supervisory Council of the company has reelected Vadims Rabsha, Chief Finance and Administrative Officer, as the Member of the Board for another term of the office - three years.

The reason for the reelection - expiry of the term of the office on 13 October 2014.

V. Rabsha doesn't own shares of JSC "Grindeks".

The Chairman of the Board Juris Bundulis and the Member of the Board Sergejs Batalins continue their work in the Board of JSC "Grindeks".

"Grindeks" is the leading pharmaceutical company in the Baltic States. Main fields of action are research, development, manufacturing and sales of original products, generics and active pharmaceutical ingredients. "Grindeks" Group consists of 4 subsidiary companies in Latvia, Estonia and Russia; representative offices are opened in 13 countries.

"Grindeks" specializes in the heart and cardiovascular, CNS and anti-cancer medication therapeutic groups. The portfolio of "Grindeks" products consists of successful combination of branded products and generic medications - including brand products Mildronate® and Ftorafur®, as well as more than 100 effective and safe medications. Currently "Grindeks" manufactures 25 active pharmaceutical ingredients.

Products of the company are exported to 59 countries and its export comprises more than 95% of the total turnover. The main markets are: Russia and other CIS countries, the Baltic States, Germany, the Netherlands, Japan and the U.S.

To increase production capacity and develop infrastructure, since 2002 the company has accomplished many significant investment projects, investing 70.7 million euros over the years.

JSC "Grindeks" shares are listed on the Official List of "NASDAQ OMX Riga". Major shareholders of JSC "Grindeks" are Kirovs Lipmans - 33.29%, "AB.LV Private Equity fund 2010" - 22.66%, Anna Lipmane - 16.69%, "Swedbank" AS Clients Account (nominee account) - 10.47%.